METTL14 induces degradation of solute carrier family seven member 11 (SLC7A11) in a YTHDF2-dependent pathway, and the HIF-1α/METTL14/YTHDF2/SLC7A11 axis is a potential therapeutic target for HCC interventional embolization therapy. This evidence concerns the gene SLC7A11 and hepatocellular carcinoma.